ROYALTY PHARMA PLC- CL A (RPRX) Stock Analyst Ratings
NASDAQ:RPRX • GB00BMVP7Y09
45.12 USD
+0.01 (+0.02%)
At close: Feb 20, 2026
45.12 USD
0 (0%)
After Hours: 2/20/2026, 8:03:34 PM
ChartMill assigns a Buy % Consensus number of 86% to RPRX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 48.57. This target is 7.65% above the current price.
- RPRX was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about RPRX.
- In the previous month the buy percentage consensus was at a similar level.
- RPRX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-27 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-11 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-30 | Goldman Sachs | Initiate | Buy |
| 2025-07-22 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-10-25 | Citigroup | Maintains | Buy -> Buy |
| 2024-08-14 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-07-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-06-03 | UBS | Downgrade | Buy -> Neutral |
| 2024-04-12 | B of A Securities | Maintains | Buy -> Buy |
| 2024-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-20 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-11-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-07-11 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-04-10 | Morgan Stanley | Maintains | Overweight |
| 2023-02-16 | UBS | Maintains | Buy |
| 2022-12-06 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-10-18 | JP Morgan | Maintains | Overweight |
| 2022-08-08 | Morgan Stanley | Maintains | Overweight |
| 2022-07-14 | Tigress Financial | Maintains | Buy |
| 2022-06-14 | UBS | Initiate | Buy |
| 2022-05-13 | ScotiaBank | Initiate | Outperform |
| 2022-04-27 | Goldman Sachs | Initiate | Buy |
| 2022-04-14 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2021-10-29 | Citigroup | Upgrade | Neutral -> Buy |
ROYALTY PHARMA PLC- CL A / RPRX FAQ
What do analysts expect the price target to be for ROYALTY PHARMA PLC- CL A (RPRX)?
14 analysts have analysed RPRX and the average price target is 48.57 USD. This implies a price increase of 7.65% is expected in the next year compared to the current price of 45.12.
Can you provide the consensus rating for ROYALTY PHARMA PLC- CL A stock?
The consensus rating for ROYALTY PHARMA PLC- CL A (RPRX) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.